Cargando…

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

Detalles Bibliográficos
Autor principal:	Seymour, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Counterpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864649/ https://www.ncbi.nlm.nih.gov/pubmed/34965297 http://dx.doi.org/10.1182/bloodadvances.2019001205

Ejemplares similares

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
por: Brem, Elizabeth A., et al.
Publicado: (2022)

P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation
por: Deeg, H. Joachim
Publicado: (2022)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Counterpoint: Flexibilization of Fasting for Laboratory Determination of the Lipid Profile in Brazil: Science or Convenience?
por: Izar, Maria Cristina de Oliveira
Publicado: (2018)

Research methods in international business: The challenge of complexity
por: Eden, Lorraine, et al.
Publicado: (2020)

Why the world economy needs, but will not get, more globalization in the post-COVID-19 decade
por: Ciravegna, Luciano, et al.
Publicado: (2021)

Family-owned multinational enterprises in the post-pandemic global economy
por: Calabrò, Andrea, et al.
Publicado: (2022)

What merits greater scholarly attention in international business?
por: Grøgaard, Birgitte, et al.
Publicado: (2022)

Capitalizing on the uniqueness of international business: Towards a theory of place, space, and organization
por: Beugelsdijk, Sjoerd
Publicado: (2022)

International business and Africa: Theoretical and applied challenges, and future directions
por: Kamoche, Ken, et al.
Publicado: (2023)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment
por: Umpierrez, Guillermo E., et al.
Publicado: (2013)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

A Critical Analysis of the Clinical Use of Incretin-Based Therapies : Are the GLP-1 therapies safe?
por: Butler, Peter C., et al.
Publicado: (2013)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients: It is time to face the evidence
por: Malanda, Uriëll L., et al.
Publicado: (2013)

2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management
por: Terkelsen, Christian Juhl, et al.
Publicado: (2013)

Point: Incident Exposures, Prevalent Exposures, and Causal Inference: Does Limiting Studies to Persons Who Are Followed From First Exposure Onward Damage Epidemiology?
por: Vandenbroucke, Jan, et al.
Publicado: (2015)

Glucose Variability
por: Service, F. John
Publicado: (2013)

Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients: Right answer, but wrong question: self-monitoring of blood glucose can be clinically valuable for noninsulin users
por: Polonsky, William H., et al.
Publicado: (2013)

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
por: Nauck, Michael A.
Publicado: (2013)

Should Local Excision After Neoadjuvant Therapy Be Included in the National Guidelines for the Treatment of Locally Advanced Rectal Cancer?
por: Aref, Amr, et al.
Publicado: (2022)

Insulin Analogs—Is There a Compelling Case to Use Them? No!
por: Davidson, Mayer B.
Publicado: (2014)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?
por: Lachin, John M.
Publicado: (2010)

“Deficiency” of Mitochondria in Muscle Does Not Cause Insulin Resistance
por: Holloszy, John O.
Publicado: (2013)

Burnout in Medicine: Are We Asking the Right Questions?
por: DePorre, Alexandra, et al.
Publicado: (2023)

PLEASE DON'T REGULATE MY INTERNALITIES
por: Mannix, Brian F., et al.
Publicado: (2015)

COUNTERPOINT: Tracheostomy in Patients With COVID-19: Should We Do It Before 14 Days? No
por: Pandian, Vinciya, et al.
Publicado: (2021)

POINT: Tracheostomy in Patients With COVID-19: Should We Do It Before 14 Days? Yes
por: Brenner, Michael J., et al.
Publicado: (2021)

A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: A1C remains the gold standard outcome predictor in diabetic dialysis patients
por: Kalantar-Zadeh, Kamyar
Publicado: (2012)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment
por: Rosko, Ashley E, et al.
Publicado: (2014)

Counterpoint: Clinical Islet Transplantation: Not Ready for Prime Time
por: Khan, Mahfuzul H., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ekcnb0n56tb39kqdftvrpn6e10